Top Story

Fibroblast growth factor 23 linked to rare diseases, CKD

May 19, 2015

NASHVILLE, Tenn. — Hypophosphatemic rickets, tumor-induced osteomalacia and chronic kidney disease may at first appear different from one another, yet they share a common thread — fibroblast growth factor 23, known as FGF23, plays an important role in all three.

According to a presenter at the 24th annual American Association of Clinical Endocrinologists Scientific & Clinical Congress, FGF23, a circulating endocrine hormone of the fibroblast growth factor family first discovered in 2000, promotes phosphate waste in the kidneys, affects the body’s ability to synthesize vitamin D and may even be a novel cardiovascular risk factor.

Rifka Schulman Meeting News Coverage

Pamidronate preserves renal function, improves mortality in chronic critical illness

May 16, 2015
NASHVILLE, Tenn. — Use of the intravenous bisphosphonate pamidronate to prevent bone resorption was associated with improved mortality, ventilator discontinuation…
Merril Mageli Meeting News Coverage

CV biomarkers unchanged following oral testosterone therapy

May 15, 2015
NASHVILLE, Tenn. — Daily oral testosterone did not significantly increase biomarkers of cardiovascular risk in hypogonadal men, compared with transdermal…

Risks, rewards increase for older transgender adults

May 1, 2015
When Olympic gold medalist and reality star Bruce Jenner came out as transgender in a high-profile television interview, a national audience was able to put a well-known…
CME
Real-world Use of Anti-VEGF Therapy

Real-world Use of Anti-VEGF Therapy

This activity is supported by an educational grant from Genentech, Inc.

Anti-VEGF is well established as first-line therapy for the treatment of diabetic macular edema (DME) and age-related…
More »
Meeting News Coverage Video
4131397887001 th

Vlog: Global endocrinology community gathers for ICE/ENDO 2014

June 21, 2014
Ronald Tamler, MD, PhD, MBA, clinical director of the Mount Sinai Diabetes Center and a member of the Endocrine Today
More »
CME
low no

Low- and No-Calorie Sweeteners in Weight Management: What Do You Need to Know?

This activity is supported by an educational grant from the American Beverage Association.

The use of low- and no-calorie sweeteners continues to grow as consumers continue to purchase foods and beverages…
More »
Meeting News Coverage

Fibroblast growth factor 23 linked to rare diseases, CKD

May 19, 2015
NASHVILLE, Tenn. — Hypophosphatemic rickets, tumor-induced osteomalacia and chronic kidney disease may at first appear different from one…
Rifka Schulman Meeting News Coverage

Pamidronate preserves renal function, improves mortality in chronic critical illness

May 16, 2015
NASHVILLE, Tenn. — Use of the intravenous bisphosphonate pamidronate to prevent bone resorption was associated with improved mortality…
Merril Mageli Meeting News Coverage

CV biomarkers unchanged following oral testosterone therapy

May 15, 2015
NASHVILLE, Tenn. — Daily oral testosterone did not significantly increase biomarkers of cardiovascular risk in hypogonadal men, compared with…

Risks, rewards increase for older transgender adults

May 1, 2015
When Olympic gold medalist and reality star Bruce Jenner came out as transgender in a high-profile television interview, a national audience was able…
In the Journals

Average vocal pitch decrease linked to testosterone dosing

April 17, 2015
Dose- and concentration-dependent decrease in average vocal pitch was found among women with higher levels of testosterone administration over 24…
Rowan T. Chlebowski, MD, PhD In the Journals

Hormone therapy affects breast cancer risk differently over time

April 16, 2015
The risk for breast cancer associated with use of menopausal hormone therapy changes over time, according to an analysis of two Women’s Health…
In the Journals

Withholding tamoxifen for 2 weeks prior to breast reconstruction may mitigate thrombotic risk

April 15, 2015
According to researchers, tamoxifen may have been overestimated previously as a microvascular thrombotic risk factor, with data suggesting that…
In the Journals

GH therapy appears safe in children without risk factors for cancer

April 14, 2015
In children without known risk factors for developing cancer, the use of growth hormone therapy appears to be safe and does not confer an increased…

Orphan drug shows promise in Prader-Willi syndrome

March 28, 2015
Ten weeks of therapy with a diazoxide choline controlled-release tablet appeared to help control hyperphagia and reduce antisocial behaviors…
In the Journals

HT may reduce mortality risk in statin-treated postmenopausal women

March 20, 2015
In women treated with statins, hormone therapy appears to decrease the risk for death from any cause, according to research published in…
More Headlines »
morganatic-roan